Low-dose calcium supplementation during pregnancy in low and middle-income countries: A cost-effectiveness analysis
Calcium supplementation during pregnancy can reduce the risk of preeclampsia and preterm birth. Few countries have implemented WHO-recommended high-dose calcium supplementation (1500-2000mg/day), due to adherence and cost concerns. However, low-dose calcium supplementation (one 500mg tablet daily) has recently been shown to be similarly efficacious as high-dose supplementation. We assessed the cost-effectiveness of low-dose calcium supplementation during pregnancy, in low- and middle-income countries (LMICs) with low dietary calcium intake. To do so, we conducted a mathematical modelling analysis in which we estimated the lifetime health outcomes (cases, deaths, and DALYs averted) and costs of low-dose calcium supplementation provided through routine antenatal care to women giving birth in 2024, as compared to no supplementation. We assessed costs (2022 USD) from a health system perspective, including cost-savings from averted care for preeclampsia and preterm birth. This analysis showed that low-dose calcium supplementation could prevent 1.3 (95% uncertainty interval: 0.2, 2.6) million preterm births (a 10% (2, 18) reduction), 1.8 (1.0, 2.8) million preeclampsia cases (a 23% (14, 32) reduction), as well as 5.9 (1.3, 12.9) million disability-adjusted life years (DALYs). Intervention costs would be $267 (220, 318) million and produce cost-savings of $56 (26, 86) million, with incremental costs per DALY averted of $90 (38, 389) across all countries, and a return on investment of 19.1 (3.8, 39.5). The intervention was cost-effective in 119 of 129 countries modeled when compared to setting-specific cost-effectiveness thresholds. While there was substantial uncertainty in several inputs, cost-effectiveness conclusions were robust to parameter uncertainty and alternative analytic assumptions. Based on these results, low-dose calcium supplementation provided during pregnancy is cost-effective for prevention of preeclampsia and preterm birth in most LMICs.
Authors
- Wafaie Fawzi (ORCID: https://orcid.org/0000-0002-2908-600X)
- Andrea B. Pembe (ORCID: https://orcid.org/0000-0002-8090-3298)
- Cara A. Yelverton (ORCID: https://orcid.org/0000-0002-6979-756X)
- Honorati Masanja (ORCID: https://orcid.org/0000-0002-3860-7348)
- Pratibha Dwarkanath (ORCID: https://orcid.org/0000-0002-9843-1057)
- Happiness Pius Saronga (ORCID: https://orcid.org/0000-0002-1946-4855)
- Alfa Muhihi (ORCID: https://orcid.org/0000-0002-4477-7300)
- Nicolas A. Menzies (ORCID: https://orcid.org/0000-0002-2571-016X)
- Poornima Ravi (ORCID: https://orcid.org/0000-0001-7220-4676)
- Christopher R. Sudfeld (ORCID: https://orcid.org/0000-0002-3203-3638)
- Anura V. Kurpad (ORCID: https://orcid.org/0000-0001-7998-2438)
- Hong Cui (ORCID: https://orcid.org/0000-0001-5734-825X)
- Vinaya Poornima
- Mary M. Sando
Institutions
- Ifakara Health Institute (TZ)
- Muhimbili University of Health and Allied Sciences (TZ)
- St. John's National Academy of Health Sciences (IN)
- St.John's Medical College Hospital (IN)
- Harvard Global Health Institute (US)
- Africa Academy for Public Health (TZ)
Publication Details
- Journal
- PLOS Global Public Health
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1371/journal.pgph.0004002
- Citations
- 2
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 4.11
Funders
- Bill and Melinda Gates Foundation